medicina59巻1号

2022年01月発行

特集 クリニカルクエスチョンで学ぶ糖尿病治療薬—糖尿病治療の新しい潮流 現場の疑問を解決—薬物治療編

Question 2　第一選択となる糖尿病治療薬とは？

著者： 藤谷淳¹ 柴田大河¹

所属機関： ¹大垣市民病院糖尿病・腎臓内科

ページ範囲：P.88 - P.91

Point
◎75歳未満の2型糖尿病患者に対する第一選択薬はメトホルミンである．
◎75歳以上の高齢者および非肥満の2型糖尿病患者にはDPP-4阻害薬を考慮する．
◎BMI 30 kg/m²以上の高度肥満合併2型糖尿病の場合は，第一選択薬としてGLP-1受容体作動薬を検討する．
◎BMI 18.5 kg/m²未満のやせ型症例は，第一選択薬としてインスリン注射も考慮する．

参考文献

1）Ong CR, et al：Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 29：2361-2364, 2006

2）Knowler WC, et al：Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346：393-403, 2002

3）American Diabetes Association：2. Classification and diagnosis diabetes；Standards of medical care in diabetes-2021. Diabetes Care 44（Suppl 1）：S111-S124, 2021

4）日本糖尿病学会：糖尿病診療ガイドライン2019，南江堂，pp 21-30，2019

5）UK Prospective Diabetes Study（UKPDS）Group：Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes（UKPDS 34）. Lancet 352：854-865, 1998

6）Park H, et al：Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes；Meta-analysis. Ann Pharmacother 46：1453-1469, 2012

7）Green JB, et al：Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373：232-242, 2015

8）Sccirica BM, et al：Heart failure, saxagliptin, and diabetes mellitus；Observations from the SAVOR-TIMI 53 randomized trial. Circulation 130：1579-1588, 2014

9）Raskin P, et al：Glycaemic control with liraglutide；The phase 3 trial programme. Int J Clin Pract Suppl 167：21-27, 2010

10）Miyagawa J, et al：Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes；A 26-week randomized phase Ⅲ study. Diabetes Obes Metab 17：974-983, 2015

11）Marso SP, et al：Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375：311-322, 2016

12）Marso SP, et al：Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375：1834-1844, 2016

13）Miller ME, et al：Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358：2545-2559, 2008

14）Schopman JE, et al：The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas；A systematic review and meta-analysis. Diabetes Metab Res Rev 30：11-22, 2014

15）Packer M, et al：Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383：1413-1424, 2020

16）McMurray JJV, et al：Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381：1995-2008, 2019

17）Heerspink HJL, et al：Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383：1436-1446, 2020

18）Vial G, et al：Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 64：2254-2264, 2015

19）Hallokou-Bozec S, et al：Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS One 16：e0241651, 2021